LongASNDJun 2026
Ascendis Pharma
Baird initiated a position in Ascendis Pharma as part of an increase in exposure to commercial-stage therapeutics companies with promising growth potential. The company's…
ASND
2 published ideas on Ascendis Pharma across 2 funds — 2 long and 0 short.
Each entry below comes from a hedge fund's own investor letter, not a 13F filing, so it carries the reasoning behind the position on Ascendis Pharma: the full thesis, the risks the manager flagged, the conviction level and the time horizon. Positions may have changed since the letter was written.
Baird initiated a position in Ascendis Pharma as part of an increase in exposure to commercial-stage therapeutics companies with promising growth potential. The company's…
Baird added Ascendis Pharma as part of an increase in exposure to commercial-stage therapeutics companies with promising growth potential. Ascendis has developed a proprietary…